Defender Pharmaceuticals Phase 3 Motion Sickness Trial Results Selected for Presentation at 2023 Military Health System Research Symposium (MHSRS)
Subjects receiving DPI-386 (intranasal scopolamine gel) demonstrated significantly lower incidence of nausea, vomiting or the…
DK88 Casino Officially Launches in Malaysia
New Social Platform Discusd.com Launches to Combat the “Dead Internet” Era with Human-First Communities